Biologics Contract Manufacturing Demand to Reach 8 Mn Liters (MnL) by 2030; Urgent Need of COVID-19 Vaccine Catalyzing Growth Rate

  • Published On : Sep 25, 2020

Pharmaceuticals and biotechnology companies are outsourcing specific services from the early stages of drug development to biological contract manufacturing organizations to reduce drug manufacturing costs. Outsourcing increases drug manufacturing efficiency and facilitates flexible operational capabilities, which is expected to immensely boost biologics contract manufacturing demand. Rising prevalence of chronic and lifestyle diseases is also anticipated to propel biologics contract manufacturing demand. Besides, continuous focus by manufacturers toward adopting technologically-advanced systems to manufacture novel biologics is also expected to accelerate the demand for biologics contract manufacturing over the forecast period.

Global biologics contract manufacturing demand is expected to reach at 8 Mn liters (MnL) in 2030, exhibiting an impressive CAGR of over 17% during the forecast period (2020 2030).

Key Takeaways from Biologics Contract Manufacturing Demand Study

  • Leading global CDMOs are focusing on expansion of their manufacturing capabilities with high flexibility and rapid operation capacity as biologics contract manufacturing demand is high. With the help of advanced single-use technologies, companies are able to cut batch manufacturing and cleaning time from 7 days to 1 day. This trend is expected to provide a competitive-edge to companies in terms of capacity, cost, convenience, and operational efficacy.
    • For instance, in Oct 2018, Thermo Fisher Scientific Inc. announced a US$ 50 million (€44 million) expansion at a CDMO plant in St Louis, Missouri, U.S., to add 16,000 L of single-use capacity due to extremely strong growth in demand for commercial biologic manufacturing. As per the company, the facility will be the largest outsourced single-use biologics site in North America.
  • With advancements in contract solutions, leading CDMOs are focusing on the expansion of their integrated capabilities from molecule-to-finished product. This trend is significant as the acceleration of development and speed to market is becoming more crucial for biopharmaceutical therapeutic developers.
    • For example, in July 2020, Avid Bioservices and Argonaut Manufacturing Services entered into an agreement to offer biotechnology and pharmaceutical clients integrated process development, drug substance manufacturing, and drug product parenteral manufacturing, to accelerate the development and commercialization of biopharmaceutical therapeutics.
  • Viral vector and vaccines contract development and manufacturing services are expected to gain significant traction due to the COVID-19 pandemic breakout and subsequent vaccine development programs.
    • For instance, in June 2020, AGC Biologics expanded its development capacities for pDNA services at the Heidelberg site, Germany, to meet the growing need for process development and manufacturing for plasmid DNA (pDNA).
  • Europe is expected to be the most lucrative region and with a revenue share of around one-third in global biologics contract manufacturing demand in 2020, owing to the presence of leading CDMO facilities in the region.

“Technological advancements to improve the manufacturing efficiency of biologics at low cost is expected to flourish market growth opportunities and provide a competitive advantage to market players in terms of innovation,” says a PMR analyst.

View Report Table of Contents, Figures, and Tables 

Doubling Industry Capacity by 2022-2023 amid COVID-19 Pandemic

The COVID-19 pandemic is becoming an industry changing milestone by providing opportunities to global CDMOs - small as well big CDMO companies. Local government and industry funds are being targeted toward rapid expansion of industry capacity in order to meet the unmet demand for vaccine development and commercialization amid the COVID-19 crisis.

For instance, in June 2020, Fujifilm Diosynth Biotechnologies announced the investment of 100 billion Yen (US$ 928 Million) to expand its large-scale biologics production facility in Denmark.

Expansion of Manufacturing Capacity - Imperative Strategy for Market Players

Key players involved in biologics contract manufacturing are looking forward to expand their manufacturing capacities to meet global demand. Leading companies are expanding their production capabilities and capacities to become the preferred choice for innovative biopharmaceutical companies and hold on to a strong position in the market.

For instance, in January 2019, Boehringer Ingelheim Biopharmaceuticals China expanded its commercial manufacturing capacities. The company installed an additional bioreactor, all needed utility, and infrastructure for GMP operations.

What Does the Report Cover?   

Persistence Market Research offers a unique perspective and actionable insights on biologics contract manufacturing demand in its latest study, presenting historical demand assessment of 2015 2019 and projections for 20202030, on the basis of platform (mammalian and microbial), application (commercial and clinical) product (monoclonal antibodies, recombinant proteins, vaccines, insulin, interferons, growth factors, and others), and therapeutic area (oncology, autoimmune disease, metabolic disease, ophthalmology, cardiovascular disease, infectious disease, neurology, respiratory disorders, and others), across seven key regions.

For additional insights on how biologics contract manufacturing demand will unfold over the next decade, write to the analyst at

PMR’s Expertise in Life Sciences and Transformational Health

Our expert team of industry analysts comprising management graduates, medical professionals, engineers, and project managers provides insights on emerging therapy areas, diagnostic tools, medical devices and components, reimbursement and market access, biotechnology, and life science research products and services to equip decision makers with sound inputs and strategic recommendations. Click here to learn more about how we zero in on the critical aspects of this industry.

Back To Top